Haveli Investment Management LLC Takes Position in Certara, Inc. $CERT

Haveli Investment Management LLC acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,400,000 shares of the company's stock, valued at approximately $48,470,000. Certara comprises 0.0% of Haveli Investment Management LLC's holdings, making the stock its 2nd largest holding. Haveli Investment Management LLC owned 4.85% of Certara as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CERT. Osaic Holdings Inc. boosted its holdings in Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock valued at $41,000 after purchasing an additional 1,175 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of Certara by 11.7% during the 2nd quarter. Corient Private Wealth LLC now owns 12,362 shares of the company's stock valued at $144,000 after buying an additional 1,295 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in shares of Certara by 8.7% in the second quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company's stock worth $127,000 after purchasing an additional 1,558 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in shares of Certara by 2.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company's stock valued at $663,000 after acquiring an additional 1,597 shares in the last quarter. Finally, Nicolet Advisory Services LLC increased its holdings in shares of Certara by 7.4% during the 3rd quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company's stock valued at $396,000 after acquiring an additional 2,100 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Trading Down 0.5%

Shares of Certara stock traded down $0.04 during trading on Friday, hitting $8.37. The stock had a trading volume of 704,299 shares, compared to its average volume of 3,637,563. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.28 billion, a PE ratio of -18.60 and a beta of 1.44. The stock has a 50 day simple moving average of $7.31 and a 200 day simple moving average of $6.46. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The company's quarterly revenue was down 10.8% on a year-over-year basis. During the same period last year, the firm earned $0.07 earnings per share. On average, research analysts expect that Certara, Inc. will post 0.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Stephens lowered their target price on Certara from $10.00 to $9.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. Barclays lifted their price target on Certara from $6.50 to $7.50 and gave the company an "equal weight" rating in a research report on Wednesday, August 5th. BMO Capital Markets reduced their target price on Certara from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Tuesday, May 12th. Weiss Ratings raised Certara from a "sell (e+)" rating to a "sell (d)" rating in a research note on Wednesday, August 5th. Finally, Robert W. Baird dropped their price target on Certara from $7.00 to $6.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $8.28.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company's offerings are divided into software tools and consulting services.